{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:19:07Z","timestamp":1792811947021,"version":"4.5.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>In the US, methadone treatment can only be provided to patients with opioid use disorder (OUD) through federal and state-regulated opioid treatment programs (OTPs). There is a shortage of OTPs, and racial and geographic inequities exist in access to methadone treatment. The National Institute on Drug Abuse Clinical Trials Network convened the Methadone Access Research Task Force to develop a research agenda to expand and create more equitable access to methadone treatment for OUD. This research agenda included mechanisms that are available within and outside the current regulations. The task force identified 6 areas where research is needed: (1) access to methadone in general medical and other outpatient settings; (2) the impact of methadone treatment setting on patient outcomes; (3) impact of treatment structure on outcomes in patients receiving methadone; (4) comparative effectiveness of different medications to treat OUD; (5) optimal educational and support structure for provision of methadone by medical providers; and (6) benefits and harms of expanded methadone access. In addition to outlining these research priorities, the task force identified important cross-cutting issues, including the impact of patient characteristics, treatment, and treatment system characteristics such as methadone formulation and dose, concurrent behavioral treatment, frequency of dispensing, urine or oral fluid testing, and methods of measuring clinical outcomes. Together, the research priorities and cross-cutting issues represent a compelling research agenda to expand access to methadone in the US.<\/jats:p>","DOI":"10.1080\/08897077.2021.1975344","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T06:21:04Z","timestamp":1633414864000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":41,"title":["Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-1526","authenticated-orcid":false,"given":"Paul J.","family":"Joudrey","sequence":"first","affiliation":[{"name":"Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Bart","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Brooner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Brown","sequence":"additional","affiliation":[{"name":"START Treatment and Recovery Centers, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dickson-Gomez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2453-8871","authenticated-orcid":false,"given":"Adam","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Health, Penn State University, State College, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Liebschutz","sequence":"additional","affiliation":[{"name":"Center for Research on Health Care, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2055-3425","authenticated-orcid":false,"given":"Edward","family":"Nunes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-2894","authenticated-orcid":false,"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[{"name":"Department of Public Health &amp; Preventive Medicine, Oregon Health &amp; Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Szapocnik","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami, Coral Gables, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Division of Mood Disorders, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Internal Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Williams","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, Department of Psychiatry, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzy","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine and Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, Yale School of Public Health, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17477"},{"issue":"2","key":"e_1_3_5_3_1","first-page":"14","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2014","unstructured":"Mattick RP, , Breen C, , Kimber J, , Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. 2014;38(2):14\u201323.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2018.05162"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12562"},{"key":"e_1_3_5_6_1","volume-title":"The CBHSQ report","author":"Alderks CE.","year":"2013","unstructured":"Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003\u20132015 (update). In: The CBHSQ report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2013. Accessed June 9, 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK469748\/"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107968"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1624"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.03.028"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228755"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.035"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1300\/J465v28n02_02"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2017.05.002"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13456"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00880-7"},{"key":"e_1_3_5_17_1","first-page":"413","article-title":"Barriers and facilitators to buprenorphine prescribing for opioid use disorder in the Veterans Health Administration During COVID-19","author":"Kelley AT","year":"2020","unstructured":"Kelley AT, , Dungan MT, , Gordon AJ. Barriers and facilitators to buprenorphine prescribing for opioid use disorder in the Veterans Health Administration During COVID-19. J Addict Med. 2020;4:413\u2013418.","journal-title":"J Addict Med"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1809609"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02887-1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18223"},{"key":"e_1_3_5_21_1","first-page":"108552","article-title":"Changes in methadone take-home dosing before and after COVID-19","author":"Amram O","year":"2021","unstructured":"Amram O, , Amiri S, , Thorn EL, , Lutz R, , Joudrey PJ. Changes in methadone take-home dosing before and after COVID-19. J Subst Abuse Treat. Published online June 24, 2021;108552.","journal-title":"J Subst Abuse Treat"},{"key":"e_1_3_5_22_1","unstructured":"SAMHSA. Opioid Treatment Program (OTP) Guidance. Published 2020. https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf."},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000679"},{"key":"e_1_3_5_24_1","unstructured":"Drug Enforcement Adminstration. COVID-19 information page. Diversion Control Division. Accessed April 6 2021. https:\/\/www.deadiversion.usdoj.gov\/coronavirus.html."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108288"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctvk12rb0"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00055-3"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-040617-013526"},{"key":"e_1_3_5_29_1","doi-asserted-by":"crossref","unstructured":"Leshner AI Mancher M. Medications for opioid use disorder save lives. National Academies of Sciences Enginneering and Medicine. Published online 2019.","DOI":"10.17226\/25310"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4801-3"},{"key":"e_1_3_5_31_1","unstructured":"SAMHSA. Federal Guidelines for Opioid Treatment Programs. 2015. https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/pep15-fedguideotp.pdf."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.1511"},{"key":"e_1_3_5_33_1","unstructured":"GovRegs.com. 42 CFR 8.12 - Federal opioid treatment standards. Accessed November 4 2020. https:\/\/www.govregs.com\/regulations\/expand\/title42_chapterI_part8_subpartC_section8.12#title42_chapterI_part8_subpartC_section8.12."},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2149"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15087"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.020"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.08.037"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/adaw.32907"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2015.1059225"},{"key":"e_1_3_5_40_1","unstructured":"Department of Health and Human Services. Methadone maintenance in primary care program. Published online 2000. https:\/\/www.samhsa.gov\/sites\/default\/files\/programs_campaigns\/medication_assisted\/dear_colleague_letters\/2000-colleague-letter-methadone-medical-maintenance.pdf."},{"key":"e_1_3_5_41_1","doi-asserted-by":"crossref","unstructured":"Wu LT John WS Morse E . Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasbility clinical trial. Addiction. 2021.","DOI":"10.1111\/add.15641"},{"issue":"5642","key":"e_1_3_5_42_1","first-page":"63","article-title":"The NIH roadmap","volume":"302","author":"Zerhouni E","year":"2003","unstructured":"Zerhouni E. The NIH roadmap. Am Assoc Adv Sci. 2003;302(5642):63\u201372.","journal-title":"Am Assoc Adv Sci."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.06.001"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000310"},{"key":"e_1_3_5_45_1","doi-asserted-by":"crossref","unstructured":"Gliklich RE Dreyer NA Leavy MB Christian JB. 21\u2009st Century patient registries: registries for evaluating patient outcomes: a user's guide: Addendum [Internet]. Published online 2018.","DOI":"10.23970\/AHRQREGISTRIESEBOOK"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05051-9"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3206"},{"key":"e_1_3_5_50_1","article-title":"Sublingual buprenorphine\/naloxone versus injection naltrexone for opioid use disorder: can patient characteristics guide choice of treatment?","author":"Nunes EV","unstructured":"Nunes EV, , Scodes JM, , Paylicova M, . Sublingual buprenorphine\/naloxone versus injection naltrexone for opioid use disorder: can patient characteristics guide choice of treatment? American Journal of Psychiatry. Published Online in Press.","journal-title":"American Journal of Psychiatry."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13068"},{"key":"e_1_3_5_52_1","unstructured":"SAMHSA. A national assessment of methadone-associated mortality: background briefing report. Published online 2004. http:\/\/www.legalsideofpain.com\/uploads\/methadone_mortality_briefing.pdf."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-019-00201-9"}],"updated-by":[{"DOI":"10.1080\/08897077.2021.1990639","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000}}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2021.1975344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2021.1975344","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2021.1975344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:27:49Z","timestamp":1780507669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2021.1975344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1080\/08897077.2021.1975344"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2021.1975344","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}